Xintela
Phase 1/2Xintela is a biomedical company working in the fields of regenerative medicine and cancer, with particular focus on two areas in which there is great need for new and better treatments: cartilage damage and brain tumours.
Founded
2013
Focus
DiagnosticsCell & Gene Therapy
About
Xintela is a biomedical company working in the fields of regenerative medicine and cancer, with particular focus on two areas in which there is great need for new and better treatments: cartilage damage and brain tumours.
Funding History
4Total raised: $37.5M
Series C$15MFårnholm InvestSep 15, 2021
Series B$12MFårnholm InvestMar 15, 2019
Series A$8MIndustrifondenDec 15, 2016
Seed$2.5MUndisclosedJun 15, 2014
Company Info
TypePrivate
Founded2013
LocationLund, Sweden
StagePhase 1/2
Contact
SIMILAR COMPANIES
Basic Genomics
Pre-clinical · Stockholm
2A Pharma
Phase 1 · Stockholm
Abliva
Pre-clinical · Lund
Affibody
Phase 1 · Solna
Alligator Bioscience
Phase 1 · Lund
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile